Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Enzastaurin may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth
in different ways. Some block the ability of cancer cells to grow and spread. Others find
cancer cells and help kill them or carry cancer-killing substances to them. Enzastaurin and
bevacizumab may also stop the growth of cancer cells by blocking blood flow to the cancer.
Giving enzastaurin together with bevacizumab may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin and
bevacizumab in treating patients with locally advanced or metastatic cancer.